Standout Papers

Atezolizumab and Nab-Paclitaxel in Advanced Triple-N... 2011 2026 2016 2021 2.9k
  1. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer (2018)
    Peter Schmid, Sylvia Adams et al. New England Journal of Medicine
  2. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (2017)
    Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine
  3. Palbociclib and Letrozole in Advanced Breast Cancer (2016)
    Richard S. Finn, Miguel Martín et al. New England Journal of Medicine
  4. Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer (2011)
    José Baselga, Javier Cortés et al. New England Journal of Medicine
  5. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial (2011)
    Luca Gianni, Tadeusz Pieńkowski et al. The Lancet Oncology
  6. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial (2016)
    Massimo Cristofanilli, Nicholas C. Turner et al. The Lancet Oncology
  7. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer (2018)
    Nicholas C. Turner, Dennis J. Slamon et al. New England Journal of Medicine
  8. Predictive and Prognostic Impact of Epidermal Growth Factor Receptor Mutation in Non–Small-Cell Lung Cancer Patients Treated With Gefitinib (2005)
    Sae‐Won Han, Tae‐You Kim et al. Journal of Clinical Oncology
  9. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (2019)
    Seock‐Ah Im, Yen‐Shen Lu et al. New England Journal of Medicine
  10. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial (2016)
    Luca Gianni, Tadeusz Pieńkowski et al. The Lancet Oncology
  11. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer (2022)
    Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine
  12. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (2019)
    Mark E. Robson, Nadine Tung et al. Annals of Oncology
  13. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer (2019)
    Stephen Johnston, Miguel Martín et al. npj Breast Cancer
  14. Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial (2021)
    Eric P. Winer, Seock‐Ah Im et al. The Lancet Oncology
  15. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial (2020)
    Leisha A. Emens, Francisco J. Esteva et al. The Lancet Oncology
  16. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study (2022)
    Massimo Cristofanilli, Hope S. Rugo et al. Clinical Cancer Research
  17. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. (2022)
    Richard S. Finn, Hope S. Rugo et al. Journal of Clinical Oncology
  18. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer (2024)
    Aditya Bardia, Xichun Hu et al. New England Journal of Medicine
  19. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial. (2023)
    Dennis J. Slamon, Daniil Stroyakovskiy et al. Journal of Clinical Oncology
  20. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer (2024)
    Dennis J. Slamon, Véronique Dièras et al. Journal of Clinical Oncology
  21. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). (2024)
    Giuseppe Curigliano, Xichun Hu et al. Journal of Clinical Oncology

Immediate Impact

2 by Nobel laureates 9 from Science/Nature 97 standout
Sub-graph 1 of 17

Citing Papers

Pyridinium Rotor Strategy toward a Robust Photothermal Agent for STING Activation and Multimodal Image-Guided Immunotherapy for Triple-Negative Breast Cancer
2025 Standout
Probiotic-guided CAR-T cells for solid tumor targeting
2023 StandoutScience

Works of Seock‐Ah Im being referenced

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout

Author Peers

Author Last Decade Papers Cites
Seock‐Ah Im 23147 13475 8677 652 31.7k
Nadia Harbeck 19898 11633 12822 839 32.4k
Sibylle Loibl 19027 8106 13044 584 28.4k
Massimo Cristofanilli 25726 11443 18181 589 37.3k
Hope S. Rugo 30324 15990 11168 833 43.5k
Fabrice André 19923 12659 13758 667 36.8k
Richard Pazdur 19104 9902 4972 582 36.2k
Howard A. Burris 25010 10502 6121 737 37.4k
Jean‐Charles Soria 19265 12561 6724 675 34.0k
Javier Cortés 20283 8493 7648 709 27.3k
Richard S. Finn 15770 11183 8000 364 36.6k

All Works

Loading papers...

Rankless by CCL
2026